Multiple chemokines

Multiple chemokines refer to a group of small, secreted signaling proteins that play a fundamental role in the immune system by directing the migration of leukocytes to sites of inflammation, injury, or lymphoid tissues [1.1.1, 1.3.3]. These proteins, which include subfamilies such as CC, CXC, C, and CX3C, function as ligands for G protein-coupled receptors (GPCRs) and are essential for processes like immune surveillance, wound healing, and angiogenesis [1.1.3, 1.3.1]. In various diseases, including chronic inflammatory conditions, autoimmune disorders, and cancer, the dysregulated expression of multiple chemokines contributes to pathological cell recruitment and tissue damage [1.1.5, 1.3.4]. Because the chemokine system is characterized by significant functional redundancy—where multiple ligands can activate the same receptor and vice versa—therapeutic strategies often focus on targeting multiple chemokines or receptors simultaneously to achieve meaningful clinical outcomes [1.1.1, 1.4.1]. Drugs in this space include specific receptor antagonists, such as Maraviroc and Plerixafor, as well as experimental broad-spectrum chemokine inhibitors (BSCIs) like FX125L and NR58-3.14.3, designed to block the activity of the entire family or large subsets thereof [1.2.1, 1.2.5]. These interventions aim to disrupt the complex signaling network that drives disease progression while minimizing the impact on homeostatic immune functions [1.1.4, 1.2.4]. However, the redundancy and pleiotropy of the system present significant challenges for drug development, often requiring multi-target approaches to overcome compensatory signaling pathways [1.1.3, 1.4.1].

Other names

Chemokine familyChemotactic cytokinesIntercrinesSIS familyChemokine ligands

Antagonism of chemokine receptors and broad-spectrum inhibition of chemokine-mediated signaling through ligand neutralization or allosteric modulation [1.2.2, 1.2.4].